Prospective cohort study assesses galectin-9 as a biomarker for infertility, suggesting its potential in IVF outcomes.
Infertility rates are indeed increasing globally, which emphasizes a pressing need to identify novel biomarkers exhibiting superior potential for laboratory diagnosis and personalized clinical management. This study aimed to explore the biological role of Galectin-9 (Gal-9) in female fertility and evaluate its diagnostic potential in the In Vitro Fertilization (IVF) program. A prospective cohort study was performed on 83 follicular fluids (FF) and 19 serum-FF pairs from IVF patients, 16 serum samples from fertile women, and 12 tissue sections. Gal-9 expression was characterized by immunostaining and ELISA. The ROC analysis was employed to evaluate the overall diagnostic performance. Cell-specific ovarian Gal-9 expression and significant differences in soluble Gal-9 levels were identified in the serum and FF of fertile and infertile women. Elevated intrafollicular Gal-9 levels were linked to poor ovarian reserve, served as a predictive marker for ovarian hyperstimulation, and marked unfavorable IVF outcomes. Follicular Gal-9 levels positively correlated with peak estradiol and total daily FSH dosage. ROC analysis revealed an excellent diagnostic value of Gal-9 for predicting fertilization success and a moderate ability to predict IVF outcomes. Our findings suggest a potential role for Gal-9 in oogenesis and its promise as a diagnostic marker for predicting fertilization success in IVF. However, further studies are needed to confirm its clinical utility in assisted reproduction.
No takes yet. Share an insight, caveat, or question.
Polgár et al. (2025) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: